MedWatch

Ambu gets US approval for new product

Ambu expects to launch Vivasight 2 on the US market during Q3 of its financial year 2020/2021

Photo: Andrew Kelly/REUTERS / X02844

The US Food and Drug Administration (FDA) has approved Ambu's product Vivasight 2 DLT, a ventilation tube with a camera, for single-use purposes.

The medtech company revealed the news in connection with its Q2 report released on Wednesday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs